Telferscot Resources Inc Share Price Canadian Securities Exchange
Equities
TFS
CA87957T1066
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- | - |
15/04 | Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding | CI |
2023 | Canntab Therapeutics Limited Provide an Update on Product Delivery | CI |
Sales 2021 | - | Sales 2022 | 0.29 0 24.43 | Capitalization | 1.15Cr 0 96Cr |
---|---|---|---|---|---|
Net income 2021 | -40L - -33Cr | Net income 2022 | -30L - -25Cr | EV / Sales 2021 | - |
Net Debt 2021 | 75.05T 0 62.5L | Net Debt 2022 | 11.49L 0 9.57Cr | EV / Sales 2022 | 4,30,43,762 x |
P/E ratio 2021 |
-7.9
x | P/E ratio 2022 |
-3.02
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 86.26% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 20/16/20 | |
President | 56 | 20/16/20 | |
Chief Tech/Sci/R&D Officer | - | 15/20/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
President | 56 | 20/16/20 | |
Barry Polisuk
BRD | Director/Board Member | 61 | 11/18/11 |
Vitor Fonseca
BRD | Director/Board Member | 71 | 11/18/11 |
1st Jan change | Capi. | |
---|---|---|
+41.06% | 626.15Cr | |
-15.95% | 449.03Cr | |
+6.36% | 328.56Cr | |
-11.34% | 312.36Cr | |
-3.12% | 249.68Cr | |
+45.41% | 194.05Cr | |
-7.74% | 168.5Cr | |
-0.67% | 163.49Cr | |
-11.32% | 156.41Cr |
- Stock Market
- Equities
- PILL Stock
- TFS Stock